Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

a Global Phase 1b/2 Study evaluate the safety and early efficacy of etakafusp alfa in Combination with Rilvegostomig as a first-line treatment in combination with rilvegostomig in patients with advanced or metastatic NSCLC.

X
Trial Profile

a Global Phase 1b/2 Study evaluate the safety and early efficacy of etakafusp alfa in Combination with Rilvegostomig as a first-line treatment in combination with rilvegostomig in patients with advanced or metastatic NSCLC.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etakafusp alfa (Primary) ; Rilvegostomig (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 15 Jan 2025 New trial record
    • 07 Jan 2025 Asher Bio announced an agreement with AstraZeneca to supply etakafusp alfa (formerly known as AB248), to be evaluated in combination with rilvegostomig, in patients with advanced or metastatic NSCLC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top